A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial

Official title:

A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03776175
• Other study ID #: C3711001
• Status: Completed
• Phase: Phase 2
• Start date: January 4, 2019
• Est. completion date: October 11, 2019

Study information

• Verified date: September 2020
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571 alone, and placebo in adults with NAFLD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: October 11, 2019
• Est. primary completion date: September 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male subjects or female subjects of non childbearing potential

• Total body weight of >50 kg (110 lbs) and a BMI greater than or equal to 25 kg/m2

• Medical diagnosis of Type 2 Diabetes Mellitus (T2DM) being treated with no more than 1 acceptable oral antidiabetic drug OR Subjects without a diagnosis of T2DM that meet 2 or more of the following 5 criteria commonly associated with metabolic syndrome

• Fasting Plasma Glucose (FPG) greater than or equal to 100 mg/dL;

• Documentation of at least stage 1 hypertension or medical history of hypertension;

• Fasting serum HDL C <40 mg/dL for males and <50 mg/dL for females, or on pharmacological agents with explicit purpose to increase HDL-C;

• Fasting serum triglyceride (TG) greater than or equal to 150 mg/dL or on pharmacological agents with explicit purpose to decrease TG;

• Waist circumference greater than or equal to 40 inches (102 cm) for males and 35 inches (89 cm) for females.

• Liver fat greater than or equal to 8% measured by MRI PDFF

Exclusion Criteria:

• Subjects with acute or chronic medical or psychiatric condition.

• Subjects with any of the following clinical laboratory abnormalities:

• Fasting TG >400 mg/dL;

• AST, ALT, or GGT >2.0x ULN;

• Hemoglobin A1c (HbA1c) >7.0%;

• Fasting plasma glucose >270 mg/dL;

• Total bilirubin >1.5x ULN;

• Albumin < lower limit of normal (LLN);

• Platelet count <0.95x LLN;

• International normalized ratio (INR) greater than or equal to 1.3.

• A positive urine test for illicit drugs.

• History of regular alcohol consumption.

• Seated systolic BP>=160 mmHg and/or diastolic BP>=100 mmHg.

• Supine 12 lead ECG demonstrating a corrected QT (QTcF) interval >450 msec or a QRS interval >120 msec.

• Subjects with an estimated GFR <60 mL/min/1.73m2.

• Evidence or diagnosis of other forms of chronic liver diseases.

• Subjects with any of the following medical conditions:

• Any condition possibly affecting drug absorption (eg prior bariatric surgery, gastrectomy, ileal resection);

• Diagnosis of type 1 diabetes mellitus;

• History of congestive heart failure, unstable angina, myocardial infarction, stroke, or transient ischemic attack;

• Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin);

• Active placement of medical devices in/on thoracic or abdominal cavities such as pacemakers, defibrillators;

• Subjects with any anatomical or pathological abnormality that would either preclude or tend to confound the analysis of study data.

• Blood donation of approximately 1 pint or more within 60 days prior to dosing.

• Subjects taking prohibited concomitant medication(s) or those unwilling/unable to switch to permitted concomitant medication(s)

• Weight loss of greater than or equal to 5% within 1 month prior to Screening.

• Unwilling or unable to comply with the Lifestyle Requirements criteria of the protocol.

• Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential; fertile male subjects who are unwilling or unable to use highly effective method(s) of contraception.

• Investigator site staff members or Pfizer employees, including their family members, directly involved in the conduct of the study.

• Subjects with known prior treatment with or participation in a clinical trial involving any of the IPs

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Non-Alcoholic Fatty Liver Disease (NAFLD)

Intervention

Drug:
• PF-05221304 Monotherapy
Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
• PF-06865571 Monotherapy
Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
• Placebo
Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
• PF-05221304 and PF-06865571 Combination
Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.

Locations

Country	Name	City	State
United States	Franco Felizarta, Md	Bakersfield	California
United States	Westside Medical Associates of Los Angeles	Beverly Hills	California
United States	WR-Clinsearch, LLC	Chattanooga	Tennessee
United States	ProSciento, Inc.	Chula Vista	California
United States	New Horizons Clinical Research	Cincinnati	Ohio
United States	Sterling Research Group - Mt. Auburn	Cincinnati	Ohio
United States	Clarity Clinical Research	East Syracuse	New York
United States	Floridian Clinical Research, LLC	Hialeah	Florida
United States	High Point Clinical Trials Center	High Point	North Carolina
United States	Research Centers of America, LLC	Hollywood	Florida
United States	East-West Medical Research Institute	Honolulu	Hawaii
United States	Midwest Institute for Clinical Research	Indianapolis	Indiana
United States	Jacksonville Center for Clinical Research	Jacksonville	Florida
United States	New Orleans Center for Clinical Research	Knoxville	Tennessee
United States	University of Tennessee Medical Center - Radiology	Knoxville	Tennessee
United States	National Research Institute - Wilshire	Los Angeles	California
United States	L-MARC Research Center	Louisville	Kentucky
United States	Pharmax Research Clinic	Miami	Florida
United States	Catalina Research Institute, LLC	Montclair	California
United States	Accel Research Sites	Orlando	Florida
United States	Omega Research Maitland	Orlando	Florida
United States	Advanced Gastroenterology Associates, LLC	Palm Harbor	Florida
United States	M3 Wake Research, Inc	Raleigh	North Carolina
United States	Wake Gastroenterology	Raleigh	North Carolina
United States	National Clinical Research-Richmond, Inc.	Richmond	Virginia
United States	Clinical Trials of Texas, Inc.	San Antonio	Texas
United States	QPS-MRA, LLC-Main Office	South Miami	Florida
United States	Heartland Research Associates, LLC	Wichita	Kansas
United States	PMG Research of Wilmington, LLC	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42	Magnetic resonance imaging proton density fat fraction (MRI-PDFF) technique is an established method that enables quantification of fat content in the liver. It measures the fraction of mobile protons in the liver attributable to fat content and provides whole liver coverage so that fat content can be assessed across 8 Couinaud liver segments. Whole liver PDFF = PDFFs for (Segment I + Segment II + Segment III + Segment IVa + Segment IVb + Segment V + Segment VI + Segment VII + Segment VIII) divided by total number of segments assessed.	Baseline, Day 42
Secondary	Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included all serious and non-serious adverse events.	Baseline up to 35 days from last dose of study drug or early termination: (maximum up to Day 77)
Secondary	Number of Participants With Laboratory Abnormalities	Clinical chemistry: Bilirubin (milligram per deciliter [mg/dL]), direct bilirubin (mg/dL)>3.0*upper limit of normal (ULN), alanine aminotransferase international units per liter (U/L), aspartate aminotransferase (U/L), alkaline phosphatase (U/L), gamma glutamyl transferase (U/L)>5.0*ULN, urea nitrogen (mg/dL)>2.0*ULN, low density lipoprotein direct endpoint measure (mg/dL)>1.5*ULN, triglycerides (mg/dL)>2.0*ULN, creatinine based estimated glomerular filtration rate by modification of diet in renal disease equation and cystatin based eGFR by chronic kidney disease epidemiology collaboration equation (C <60 milliliter per minute per 1.73 square of meter), very low density lipoprotein (millimoles per liter), Cholesterol >2.0*ULN.	Baseline up to 35 days last from dose of study drug or early termination (maximum up to Day 77)
Secondary	Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure	Vital signs included systolic blood pressure, diastolic blood pressure and pulse rate.	Baseline, Post-last dose of study drug (up to Day 42)
Secondary	Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Pulse Rate	Vital signs included systolic blood pressure, diastolic blood pressure and pulse rate.	Baseline, Post- last dose of study drug (up to Day 42)
Secondary	Number of Participants Meeting Pre-Specified Electrocardiogram (ECG) Criteria	ECG criteria included: 1) PR interval (milliseconds [msec]): baseline greater than (>) 200 msec and maximum increase from baseline greater than or equal to (>=) 25 percent (%) or baseline less than or equal to (<=) 200 msec and maximum increase from baseline >=50%; 2) QRS interval (msec): maximum increase from baseline >=50%; 3) QT interval corrected using Fridericia's formula (QTcF): a) change from baseline >30 msec and <=60 msec, b) change from baseline >60 msec.	Baseline up to 35 days last dose of study drug or early termination (maximum up to Day 77)

External Links

•   To obtain contact information for a study center near you, click here.